Trial · NCT04343976

Pegylated Interferon Lambda Treatment for COVID-19

NCT04343976, Phase 2, Terminated, Raymond Chung; results first posted 2022-07-21

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Pegylated Interferon Lambda Treatment for COVID-19. Trials, record NCT04343976. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04343976

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Pegylated Interferon Lambda Treatment for COVID-19
NCT number: NCT04343976
Status: Terminated
Phases: Phase 2
Enrollment: 14 participants, actual
Lead sponsor: Raymond Chung
Conditions: COVID-19, COVID
Interventions: Pegylated interferon lambda
First posted: 2020-04-14
Last updated: 2022-07-21
Results first posted: 2022-07-21
Limitations and caveats: Enrollment was slower than anticipated due to issues operationalizing outpatient follow-up for viremic subjects discharged from hospital prior to study completion, including lack of transportation and delays contracting with home health services to offer home visits. Also, study was terminated prior to meeting enrollment goal due to a decrease in eligible subjects and lack of funding.

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Undetectable COVID PCR at Day 7	7 days	Negative COVID PCR testing 7 days after first lambda dose
Secondary	Undetectable COVID PCR at Day 3	3 days	Negative COVID PCR testing 3 days after first lambda dose
Secondary	Percentage of Subjects on Lambda vs Placebo With Symptomatic Improvement	2 weeks	Daily symptom score improvement during treatment period
Secondary	Percentage of Subjects on Lambda vs Placebo With Improved Clinical Outcomes	2 weeks	Time to event for death, intubation, hospital discharge
Secondary	Undetectable COVID PCR Testing at Day 14	14 days	Negative COVID PCR testing 14 days after first lambda dose

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Undetectable COVID PCR at Day 7	7 days	Subjects with Day 7 qPCR result of NEG (negative), meaning that no amplification was observed.	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Undetectable COVID PCR at Day 3	3 days		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Percentage of Subjects on Lambda vs Placebo With Symptomatic Improvement	2 weeks	insufficient data, analysis not performed as there the symptom improvement score was not collected and not available for analysis.
SECONDARY	Percentage of Subjects on Lambda vs Placebo With Improved Clinical Outcomes	2 weeks	Data was not collected and therefor analysis not performed.
SECONDARY	Undetectable COVID PCR Testing at Day 14	14 days	All subjects providing NP swab samples at Day 14	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Undetectable COVID PCR at Day 7	Lambda Treatment	1	Participants
Undetectable COVID PCR at Day 7	Saline Placebo	4	Participants
Undetectable COVID PCR at Day 3	Lambda Treatment	1	Participants
Undetectable COVID PCR at Day 3	Saline Placebo	4	Participants
Undetectable COVID PCR Testing at Day 14	Lambda Treatment	2	Participants
Undetectable COVID PCR Testing at Day 14	Saline Placebo	2	Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Lambda Treatment	7
Overall Study	STARTED	Saline Placebo	7
Overall Study	COMPLETED	Lambda Treatment	7
Overall Study	COMPLETED	Saline Placebo	6
Overall Study	NOT COMPLETED	Lambda Treatment	0
Overall Study	NOT COMPLETED	Saline Placebo	1

Source ClinicalTrials.gov

Adverse events14

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Shortness of Breath	Respiratory, thoracic and mediastinal disorders	Lambda Treatment	0	7	0
other	Shortness of Breath	Respiratory, thoracic and mediastinal disorders	Saline Placebo	1	7	1
other	Chest Pain	Cardiac disorders	Lambda Treatment	0	7	0
other	Chest Pain	Cardiac disorders	Saline Placebo	1	7	1
other	Stomach Pain (unspecified)	Gastrointestinal disorders	Lambda Treatment	1	7	1
other	Stomach Pain (unspecified)	Gastrointestinal disorders	Saline Placebo	0	7	0
other	Transaminitis	Hepatobiliary disorders	Lambda Treatment	1	7	1
other	Transaminitis	Hepatobiliary disorders	Saline Placebo	0	7	0
other	ICU Delirium	Psychiatric disorders	Lambda Treatment	1	7	1
other	ICU Delirium	Psychiatric disorders	Saline Placebo	0	7	0

1 to 10 of 14Source ClinicalTrials.gov

See all 14 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Lambda Treatment	0	7
Total, all-cause mortality	Saline Placebo	0	7
Total, other adverse events	Lambda Treatment	3	7
Total, other adverse events	Saline Placebo	1	7
Total, serious adverse events	Lambda Treatment	2	7
Total, serious adverse events	Saline Placebo	0	7

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
32788708	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons5

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Lambda Treatment vs Saline Placebo: Undetectable COVID PCR Testing at Day 14	Trial comparisons
Lambda Treatment vs Saline Placebo: Undetectable COVID PCR at Day 7	Trial comparisons
Lambda Treatment vs Saline Placebo: Undetectable COVID PCR at Day 3	Trial comparisons
Lambda Treatment vs Saline Placebo: deaths from any cause	Trial comparisons
Lambda Treatment vs Saline Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04343976

GET https://conductscience.org/api/trials/v1/NCT04343976/registered

API reference For AI assistants